Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMW NASDAQ:ATNFW NASDAQ:DRTSW NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.02-7.0%$0.02$0.00▼$0.05N/AN/A123,607 shs73,586 shsATNFW180 Life Sciences$0.05+1.4%$0.13$0.00▼$0.62N/AN/A501,334 shs475,237 shsDRTSWAlpha Tau Medical$0.34-3.2%$0.32$0.13▼$0.50N/AN/A18,164 shs2,900 shsSXTPW60 Degrees Pharmaceuticals$0.05-14.1%$0.06$0.01▼$0.16N/AN/A12,407 shs4,400 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-6.98%-20.00%+25.65%-31.23%+140.00%ATNFW180 Life Sciences+11.00%+5.50%-40.33%+304.55%+304.55%DRTSWAlpha Tau Medical+1.75%+3.30%-2.09%+33.10%+89.56%SXTPW60 Degrees Pharmaceuticals-14.12%+15.56%+38.36%+13.48%+28.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.02-7.0%$0.02$0.00▼$0.05N/AN/A123,607 shs73,586 shsATNFW180 Life Sciences$0.05+1.4%$0.13$0.00▼$0.62N/AN/A501,334 shs475,237 shsDRTSWAlpha Tau Medical$0.34-3.2%$0.32$0.13▼$0.50N/AN/A18,164 shs2,900 shsSXTPW60 Degrees Pharmaceuticals$0.05-14.1%$0.06$0.01▼$0.16N/AN/A12,407 shs4,400 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-6.98%-20.00%+25.65%-31.23%+140.00%ATNFW180 Life Sciences+11.00%+5.50%-40.33%+304.55%+304.55%DRTSWAlpha Tau Medical+1.75%+3.30%-2.09%+33.10%+89.56%SXTPW60 Degrees Pharmaceuticals-14.12%+15.56%+38.36%+13.48%+28.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMWApollomics 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMWApollomicsN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$641.41KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMWApollomicsN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/A0.00∞N/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMWApollomicsN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMWApollomicsN/AATNFW180 Life SciencesN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPLMWApollomicsN/AATNFW180 Life SciencesN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMWApollomics59N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableDRTSWAlpha Tau Medical80N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableAPLMW, ATNFW, SXTPW, and DRTSW HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Submits Breakthrough Therapy Designation Request to FDA for Tafenoquine in Treating Relapsing BabesiosisOctober 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals unveils name of chronic babesiosis trialOctober 9, 2025 | msn.com60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyOctober 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Launches B-FREE Chronic Babesiosis Study Following Patient Naming Competition and $5K Charity DonationOctober 9, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Highlights ARAKODA Growth PotentialSeptember 9, 2025 | tipranks.com60 Degrees Pharmaceuticals Enters New Sales AgreementSeptember 5, 2025 | tipranks.com60 Degrees Pharmaceuticals Initiates Phase II Clinical Trial of Tafenoquine for Chronic Babesiosis TreatmentAugust 19, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Reports Q2 2025 EarningsAugust 13, 2025 | tipranks.com60 Degrees Pharmaceuticals Inc (SXTP) - Investing.com UKJuly 23, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella BacteriaJuly 19, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Secures $5M in Recent OfferingJuly 18, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and WarrantsJuly 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Inc (SXTP) - Investing.comJune 30, 2025 | investing.com60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 6, 2025 | usatoday.com60 Degrees Pharmaceuticals Introduces New 8-Count Bottle for ARAKODA® Malaria ProphylaxisJune 6, 2025 | nasdaq.com60 Degrees introduces eight-count bottle format for ARAKODAJune 4, 2025 | msn.com60 Degrees announces results from an insurance claims analysis on babesiosisJune 4, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Highlights Major Discrepancies in Babesiosis Diagnosis Estimates in U.S.April 24, 2025 | nasdaq.com60 Degrees Pharmaceuticals signs Patient License Agreement with YaleApril 8, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces 2024 Annual ResultsMarch 28, 2025 | finance.yahoo.comMedia Sentiment Over TimeAPLMW, ATNFW, SXTPW, and DRTSW Company DescriptionsApollomics NASDAQ:APLMW$0.02 0.00 (-6.98%) As of 10/24/2025 03:24 PM EasternApollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.180 Life Sciences NASDAQ:ATNFW$0.05 +0.00 (+1.43%) As of 10/24/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Alpha Tau Medical NASDAQ:DRTSW$0.34 -0.01 (-3.21%) As of 10/24/2025 03:30 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.05 -0.01 (-14.12%) As of 10/24/2025 12:50 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
